MARKET COMPOSITE
AXNX - Axonics ModulationTechnologies Inc8:00:00 PM 3/28/2024
Price
$68.97
+ 0.07 (0.10%)
Axonics Modulation Technologies, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems in the United States and internationally. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence, and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was incorporated in 2012 and is based in Irvine, California.
Financials
Quarterly financials
(USD)Jun 2023Q/Q
Revenue92.9MM+31%
Gross Profit70.2MM+34%
Cost Of Revenue22.7MM+25%
Operating Income-12.1MM-16%
Operating Expenses82.3MM+23%
Net Income-7.3MM-21%
R&D8.9MM+11%
G&A10.7MM-12%
Marketing44.3MM+4%
Amortization2.3MM+3%
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    IRVINE, Calif., March 22, 2024--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics’ merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shares of Axonics’ common stock outstanding and entitled to vote at the special meeting voted in favor of adopting the merger agreement. Final voting results, as tabulated by an independen

    IRVINE, Calif., March 21, 2024--Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting.

    IRVINE, Calif., March 14, 2024--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval.

    Axonics ( NASDAQ:AXNX ) Full Year 2023 Results Key Financial Results Revenue: US$366.4m (up 34% from FY 2022). Net...

    IRVINE, Calif., February 29, 2024--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along with a parallel action in U.S. District Court for the District of Delaware. The complaint alleges that Axonics infringes two Medtronic patents that purportedly relate to a "patient programmer with automated MRI compatibility verification" for an implantable medical device.

    Comprehensive Financial Performance Drives Optimism Despite Net Loss for the Fiscal Year

    Axonics (AXNX) delivered earnings and revenue surprises of 116.67% and 0.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

    IRVINE, Calif., February 28, 2024--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2023.

    On January 31, 2024, Chief Medical Officer Karen Noblett executed a sale of 11,288 shares of Axonics Inc (NASDAQ:AXNX).

    Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or $0.34 per share (EPS), compared to $126 million or $0.09 per share a year ago and achieved adjusted3 EPS of $0.55 for